Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized ...

Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically ...
The Manila Times

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) i…

Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed ...

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- ...

Dame Bridget Ogilvie obituary

Parasitologist and director of the Wellcome Trust who oversaw the launch of the UK’s flagship genome sequencing centre ...
CIDRAPOpinion

CIDRAP Op-Ed: Why the FDA tried to bury studies showing vaccines are safe

After the rofecoxib (Vioxx) withdrawal in 2004 made painfully clear how much harm a passive reporting system can miss, ...

Moderna: mRNA Vaccine Is Only Viable In A COVID-Like Situation, Strong Sell

RSV and flu mRNA vaccines struggle with lower durability, higher side effects, and weak uptake, leading to program cuts and ...
Pharmabiz

European Commission approves Bristol Myers Squibb’s Sotyktu for the treatment of active psoriatic arthritis in adults

European Commission approves Bristol Myers Squibb’s Sotyktu for the treatment of active psoriatic arthritis in adults: Princeton, New Jersey Monday, May 11, 2026, 15:00 Hrs [IST ...
The Scientist

Slowed But Not Stalled: The Future of mRNA Vaccine Research

I n December 2020, mRNA vaccines leapt into the limelight as a response to the COVID-19 pandemic. To date, millions of people ...